Loading...
7 results
Search Results
Now showing 1 - 7 of 7
- Association of LDL-cholesterol with prognosis in patients admitted for acutely decompensated heart failurePublication . Brito, Joana; Rin, João; Duarte, Catarina; Couto Pereira, Sara Cristina; Morais, Pedro; Cunha, Nelson; Ferreira, Diogo; Santos, Rafael; Rigueira, Joana; Pinto, Fausto J.; Brito, DulceIntroduction and objectives: The association of low-density lipoprotein cholesterol (LDL-C) levels and prognosis in patients with heart failure (HF) remains uncertain. This study aimed to evaluate the prognostic significance of LDL-C in patients admitted for acutely decompensated HF and establish a safety cut-off value in this population. Methods: This retrospective, observational study included 167 consecutive patients admitted for acute HF. LDL-C levels were measured on hospital admission, and patients were categorized according to their estimated cardiovascular (CV) risk. The primary endpoint was all-cause mortality at one-year, while secondary endpoints included HF hospitalizations, major thrombotic events, and net clinical benefit. Results: During the follow-up period, 14.4% of patients died. Higher LDL-C levels were independently associated with improved survival, with a 4-fold increase in survival probability for each 1 mg/dL increase in serum LDL-C. The minimum LDL-C value not associated with increased mortality risk was 88 mg/dL. Patients with LDL-C below this cut-off had a significantly higher risk of mortality and a tendency for higher HF hospitalization risk. The net clinical benefit endpoint was also influenced by LDL-C levels, with LDL-C below 88 mg/dL associated with an increased risk of events. Conclusion: In patients admitted for acutely decompensated HF, higher LDL-C levels were associated with reduced risk of mortality. An LDL-C value below 88 mg/dL was associated with increased mortality, suggesting the need for a more liberal LDL-C target in this specific patient population. These findings highlight the importance of considering LDL-C levels in the management and risk assessment of patients with HF.
- Clinical experience of a cardio-oncology consultation at a tertiary university hospital in Portugal: an observational studyPublication . Fiuza, Manuela; Magalhaes, Andreia; Menezes, Miguel Nobre; Costa, Paula; Ribeiro, Maria Leonor; Marques, Catarina; Brás, Raquel; Vieira, Joana; Afonso, Ana I.; Morais, Pedro; Valente Silva, Beatriz; Costa, Luis; Pinto, Fausto J.Introduction: Heart disease and cancer are the two leading causes of morbidity and mortality worldwide. Advances in cancer screening and management have led to longer survival and better quality of life. Despite this progress, many cancer patients experience cardiovascular complications during and after cancer treatment. This study describes the experience of a cardio-oncology program at tertiary academic hospital. Methods: In this retrospective observational study, cancer patients referred to the CHULN cardio-oncology consultation (COC) between January 2016 and December of 2019 were included. Data collected included: patient demographics, cancer type, reason for referral, cardiovascular risk factors, cardiac and oncologic treatments and clinical outcomes. Results: A total of 520 patients (mean age: 65 ± 14 years; 65% women) were referred to the COC. The main reasons for referral were suspected heart failure (26%), pre-high risk chemotherapy assessment (20%) and decreased LVEF (15%). Pre-existing cardiovascular risk factors were common (79%) and 309 (59%) were taking cardiac medications. The most common type of malignancy was breast cancer (216, 41%) followed by gastrointestinal (139, 27%). More than half received anthracycline-based regimens (303, 58%). Most patients (401; 77%) successfully completed cancer therapy. At the time of last data collection, the majority of patients were alive (430, 83%). Cardiac-related mortality was observed in 16%. Conclusions: The close collaboration between cardiology and oncology teams and timely cardiac monitoring was the key to the majority of patients to completing their prescribed cancer therapy.
- Wells and Geneva decision rules to predict pulmonary embolism: can we use them in Covid-19 patients?Publication . Silva, B. V.; Calhaz-Jorge, Carlos; Rigueira, Joana; Rodrigues, Tiago; Silverio Antonio, P.; Morais, Pedro; Pereira, S.; Alves Da Silva, P.; Brito, J.; Plácido, Rui; Almeida, Ana G.; Pinto, Fausto J.Pulmonary embolism (PE) is a recognized complication of SARS-COV2 infection due to hypercoagulability. Before the COVID era, the need for computed tomography pulmonary angiography (CTPA) to rule out PE was determined by clinical probability, based on Wells and Geneva scores, in association with D-dimer measurements. However, patients with SARS-COV2 infection have a pro-thrombotic and pro-inflammatory state which may compromise the usefulness of these algorithms to select patients for CTPA.
- Infective endocarditis risk in patients with bicuspid aortic valve: systematic review and meta-analysisPublication . Couto Pereira, Sara Cristina; Abrantes, Ana; António, Pedro Silverio; Morais, Pedro; Santos De Sousa, Catarina Isabel; David, Cláudio; Pinto, Fausto J.; Almeida, Ana G.; Caldeira, DanielBackground: Antibiotic prophylaxis in bicuspid aortic valve patients is currently a matter of debate. Although it is no longer recommended by international guidelines, some studies indicate a high risk of infective endocarditis. We aim to evaluate the risk of native valve infective endocarditis in bicuspid aortic valve patients and compare to individuals with tricuspid aortic valve. Methods: Study search of longitudinal studies regarding infective endocarditis incidence in bicuspid aortic valve patients (compared with tricuspid aortic valve/overall population) was conducted through OVID in the following electronic databases: MEDLINE, CENTRAL, EMBASE; from inception until October 2020. The outcomes of interest were the incidence rate and relative risk of infective endocarditis. The relative risk and incidence rate (number of cases for each 10 000 persons-year) with their 95 % confidence intervals (95 %CI) were estimated using a random effects model meta-analysis. The study protocol was registered at PROSPERO CRD42020218639. Results: Eight cohort studies were selected, with a total of 5351 bicuspid aortic valve patients. During follow up, 184 bicuspid aortic valve patients presented infective endocarditis, with an incidence rate of 48.13 per 10,000 patients-year (95 %CI 22.24-74.02), and a 12-fold (RR: 12.03, 95 %CI 5.45-26.54) increased risk compared with general population, after adjusted estimates. Conclusions: This systematic review and meta-analysis suggests that bicuspid aortic valve patients have a significant high risk of native valve infective endocarditis. Large prospective high-quality studies are required to estimate more accurately the incidence of infective endocarditis, the relative risk and the potential benefit of antibiotic prophylaxis.
- Are we aiming for different metabolic targets in heart failure patients?Publication . Brito, J.; Agostinho, João R.; Duarte, C.; Silva, B.; Couto Pereira, Sara Cristina; Morais, Pedro; Cunha, Nelson; Rodrigues, Tiago; Antonio, P. S.; Santos, R.; Nunes-Ferreira, Afonso; Rigueira, Joana; Aguiar-Ricardo, Inês; Pinto, Fausto J.; Brito, DulceIntroduction: Metabolic control plays an important role on major cardiovascular events (MACE) prevention. The 2019 ESC guidelines on dyslipidaemia management recommend tighter LDL-cholesterol (LDL-C) control in order to prevent cardiovascular events. However, it is not yet proven that thigh control of dyslipidaemia, glycaemic levels and body mass index (BMI) in Heart Failure (HF) patients (pts) have an impact on prognosis. Objective: To evaluate the impact of LDL-C, HbA1c and BMI values on HF pts mortality and MACE rates.
- Mitral valve prolapse: American versus European guidelines : which one is betterPublication . Brito, J.; Rigueira, Joana; Rodrigues, Tiago; Aguiar-Ricardo, Inês; Santos, R.; Ferreira, Afonso Nunes; Cunha, Nelson; Pereira, S.; António, P. S.; Morais, Pedro; Alves Silva, P.; Valente Silva, B.; Pinto, Fausto J.; Almeida, Ana G.According to the most recent recommendations of AHA, mitral valve prolapse (MVP) is defined as systolic displacement of the mitral leaflet into the left atrium (LA) of at least 2 mm from the mitral annular plane. The ESC recommendations define MVP, flail and billowing, according to the location of the leaflet tips in relation to the coaptation plan. Differences in outcomes considering these classifications are not established.
- Non‐invasive telemonitoring improves outcomes in heart failure with reduced ejection fraction : a study in high‐risk patientsPublication . Nunes-Ferreira, Afonso; Agostinho, João R.; Rigueira, Joana; Aguiar-Ricardo, Inês; Guimarães, Tatiana; Santos, Rafael; Rodrigues, Tiago; Cunha, Nelson; António, Pedro Silvério; Couto Pereira, Sara Cristina; Morais, Pedro; Mendes Pedro, Mónica; Veiga, Fátima; Pinto, Fausto J.; Brito, DulceAims: Non-invasive telemonitoring (TM) in patients with heart failure (HF) and reduced left ventricular ejection fraction (HFrEF) may be useful in the early diagnosis of HF decompensation, allowing therapeutic optimization and avoiding re-hospitalization. We describe a TM programme in this population and evaluate its effectiveness during a 12 month period. Methods and results: We conducted a single-centre study of patients discharged from hospital after decompensated HF, allocated into three groups: prospective TM programme, prospective HF protocol follow-up programme (PFP) with no TM facilities, and retrospective propensity-matched usual care (UC). TM effectiveness was assessed by all-cause hospitalizations and mortality; HF-related hospitalization (HFH), days lost to unplanned hospital admissions/death, functional capacity and quality of life (New York Heart Association, Kansas City Cardiomyopathy Questionnaire, 6 min walk test, and plasma N-terminal pro-brain natriuretic peptide) were also evaluated. A total of 125 patients were included [65.9 ± 11.9 years, 32% female, left ventricular ejection fraction 27% (21-32)]. TM was similar to PFP regarding effectiveness; TM reduced all-cause hospitalization and mortality (HR 0.27; 95% CI 0.11-0.71; P < 0.01) and HFH (HR 0.29; 95% CI 0.10-0.89; P < 0.05) as compared with UC. TM reduced the average number of days lost due to unplanned hospital admissions or all-cause death as compared with PFP (5.6 vs. 12.4 days, P < 0.05) and UC (5.6 vs. 48.8 days, P < 0.01). Impact on quality of life was similar between TM and PFP (P = 0.36). Conclusions: In patients with HFrEF and recent HF hospitalization, non-invasive TM reduced 12 month all-cause hospitalization/mortality and HFH as compared with usual care. TM also reduced the number of days lost due to unplanned hospital admission/death as compared with either an optimized protocol-based follow-up programme or usual care.